Replies to post #146987 on Biotech Values

[masterlongevity]

how does an 80 pt research company (planned Neotope) that only expects 3 INDs by 2015 have a burn rate of $60-$80M/yr?

there are a lot of clinical stage companies with multiple products with a quarter of that burn rate

[DewDiligence]

Neotope is a pretty good name for a drug-discovery company—perhaps too good for the pipeline dregs being packaged in this new firm.

[DewDiligence]

ELN schedules shareholders’ vote on spinoff of drug-discovery business:

http://finance.yahoo.com/news/elan-announces-publication-egm-circular-070000403.html

As previously announced, and assuming…an affirmative vote of the Elan shareholders at the EGM, the Prothena business which comprises a substantial portion of Elan’s drug discovery business platform, will be separated into another company by way of a demerger. This company, previously named Neotope Corporation plc, but now named Prothena Corporation plc (Prothena), will be a new publicly traded company incorporated in Ireland.

[DewDiligence]

ELN sets exchange ratio for Prothena drug-discovery spinoff—1 share of Prothena for each 41 shares of ELN:

http://finance.yahoo.com/news/elan-announces-expected-timetable-respect-214500696.html

Prothena shares will trade on Nasdaq under the symbol PRTA starting 12/21/12; Prothena when issued shares (PRTA.WI) will trade from 12/18/12 through the close on 12/20/12.

Does anyone here care?